Mechanism
Lucence INSIGHT™ employs proprietary amplicon technology for cancer screening by analysing circulating tumour DNA (ctDNA) in the blood to detect genetic mutations. These mutations can cause uncontrolled cell growth, leading to cancer. The high sensitivity and specificity of this technology enable precise detection of early cancerous changes.
Suitable For
Lucence INSIGHT™ is recommended in conjunction with existing screening tools for:
- Individuals aged 40 and above who are not pregnant and without a history of cancer in the past 3 years.
- Individuals with an elevated risk of cancer (e.g. family history of cancer, diet, lifestyle etc).
Based on our proprietary next-generation sequencing technology, Lucence INSIGHT™ screens for the signal of cancer with a sensitivity of 80.9% and a specificity of 99%3.
Cancers covered by Lucence INSIGHT™
There are 50 cancer types covered by Lucence INSIGHT™ PLUS. Lucence INSIGHT™ covers the 12 cancers highlighted in orange.
1 Draw of Blood
Up to 50 Cancers Screened
12 - 20 Days To Results
Genetic Test / Cancer Screening
Lucence INSIGHT™ — Multi-cancer Early Screening Package
Managed by a Doctor (The fee includes doctor's consultation fee and testing fees)
Two Versions Available, Choose According to Personal Needs.
Basic Version (12 Cancer Types Covered)
Service Pricing $ 16,888
- Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastrointestinal Stromal Tumour (GIST) ,Liver Cancer, Lung Cancer (Non-small cell lung cancer, Small cell lung cancer, Pulmonary neuroendocrine tumour), Nasopharyngeal Cancer, Pancreatic Cancer, Prostate Cancer
Plus Version (50 Cancer Types Covered)
Service Pricing $ 24,188
- Extension of Basic Package (additional 38 cancer types)
- Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastrointestinal Stromal Tumour (GIST), Liver Cancer, Lung Cancer (Non-small cell lung cancer, Small cell lung cancer, Pulmonary neuroendocrine tumour), Nasopharyngeal Cancer, Pancreatic Cancer, Prostate Cancer, Bladder Cancer, Endometrial Cancer, Eye Cancer, ENT (Ear, Nose, Throat) Cancer, Kidney Cancer, Waldenstrom's Macroglobulinemia, Myeloproliferative Neoplasms, Non., Hodgkin Lymphoma, Oropharyngeal Cancer, Skin Cancer, Stomach Cancer, Acute Myeloid Leukaemia, Chronic Myeloid Leukaemia, Various cancers related to cardiovascular diseases and hematologic malignancies.
Important Notes
- Lucence INSIGHT™ screens for signals of cancer. The test does not diagnose cancer. If a positive result is found, further confirmatory diagnostic testing is recommended.
- Lucence INSIGHT™ does not predict inherited risk of cancer where it is pre-disposed within the family, such as breast cancer.
- Lucence INSIGHT™ does not replace standard of care screening. It should be used in addition to routine screening tests recommended by a doctor.
- False-positive and false-negative results do occur. False negatives can occur due to biological reasons such as low DNA shedding or small tumor size. If further confirmatory testing does not confirm cancer, it could mean that cancer is not present or that confirmatory testing was insufficient to detect the cancer signal.
- Lucence INSIGHT™ only predicts for the list of cancers indicated and not more. It does not rule out the possibility of other cancers.
- Lucence INSIGHT™ is not recommended for individuals who are pregnant, or have a history of cancer in the past 3 years.